Indian cell well being platform MFine merges with biotech firm LifeCell’s diagnostic biz

Well being tech startup MFine has agreed to merge with the diagnostics enterprise of Indian biotechnology firm LifeCell and type a brand new entity known as LifeWell.

The brand new three way partnership has additionally acquired an $80 million funding from healthcare investor OrbiMed.


Collectively, the businesses have a mixed consumer base of over six million, which is anticipated to additional develop to greater than 50 million over the subsequent 4 years. 

Primarily based on a press launch, LifeWell plans to construct its nationwide laboratory community by buying and merging with “​​prime quality radiology and pathology lab property”.

OrbiMed’s funding within the newly established entity can be used for strategic investments in insurance coverage know-how and different companions.

Following the merger, MFine will stay a consumer-facing well being app that provides teleconsultations, care plans, diagnostic checks, IP concierge, e-pharmacy and company subscriptions.


The merger comes as MFine restructured its enterprise in Could. Primarily based on information reviews, the corporate laid off round 500 or half of its complete workforce as funding has depleted for Indian startups. It final raised $48 million in a Collection C funding spherical in September final yr. Since then, MFine has shifted its focus to extra worthwhile areas similar to company service and insurance coverage partnerships.

Early this yr, MFine launched a number of well being monitoring options on its cell app, together with for coronary heart charge, blood strain, and blood sugar.


With LifeCell’s full-stack diagnostics and MFine’s deep know-how capabilities, the three way partnership is claimed to be uniquely positioned in India’s rising healthcare supply market, which outpatient phase alone is price $20 billion. 

“We see a big alternative in India’s healthcare supply market with a lot of the market nonetheless unorganised and client demand for high-quality companies hovering,” Sunny Sharma, senior managing director of OrbiMed Asia, stated.

“General, healthcare supply is reworking worldwide with the speedy adoption of latest applied sciences similar to genomics and digital well being. This mixture paves the way in which to create a brand new market chief that meets the rising buyer expectations,” LifeCell CEO Mayur Abhaya stated about its merger with MFine.

“With this three way partnership, we see immense potentialities of delivering on-demand healthcare with excellent client expertise… Along with [LifeCell], we now have an built-in care supply expertise that is unmatched and might scale quickly throughout the nation,” MFine co-founders Prasad Kompalli and Ashutosh Lawania additionally commented.

Supply hyperlink

What's your reaction?

In Love
Not Sure

You may also like

More in:Health

Leave a reply

Your email address will not be published. Required fields are marked *